US companies could avoid warning letters under proposed good manufacturing practice pilot
This article was originally published in Clinica
Executive Summary
The FDA is proposing to introduce a pilot programme that would make it possible for US companies to avoid an embarrassing warning letter even if the agency finds deficiencies in their good manufacturing practices (GMP).